Kazia Therapeutics received a $2 million milestone payment as Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib for treating rare epilepsies linked to mTOR pathway disorders, including focal cortical dysplasia type 2 and tuberous sclerosis complex. This trial marks a significant expansion of paxalisib's development beyond cancer, targeting neurological diseases with unmet treatment needs. Sovargen holds exclusive rights outside China and is responsible for further development and commercialization, with Kazia eligible for up to $17 million more in milestones plus royalties. The study's progress could open new therapeutic avenues for patients with drug-resistant seizures.
Kazia Therapeutics' news on Sovargen dosing the first patient in a Phase 1b/2a trial is presented with Pluang's Health sector data for context. Among 95 priced US health stocks on Pluang as of Sep 22, 2026 18:11 WIB, 50 advanced while 38 declined. Notably, ADPT traded at USD 27.01 with a 3.05% drop and full buy-side order activity, contrasting with CTXR's USD 0.59 price and 2.91% gain alongside 97% buy orders, while ABEO fell 1.76% to USD 5.57.
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...
